LIPO LIPELLA PHARMACEUTICALS INC.
Pharmaceutical Preparations · OTC · SEC CIK 1347242 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.4%
TTM net income YoY-25.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,387.9%
Net margin-1,367.4%
FCF margin—
EBITDA margin-1,387.2%
Returns
ROE-361.8%
ROA-236.4%
ROIC (approx.)—
Asset turnover0.17x
Leverage & solvency
Liabilities / assets36.7%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-24.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q3*2025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $86,727 | $129,390 | $173,666 | $80,380 | $136,431 | $145,880 | $120,842 |
| R&D expense | $720,973 | $791,581 | $993,475 | $1.06M | $1.05M | $661,558 | $842,600 | $454,200 |
| SG&A expense | $553,299 | $651,721 | $463,736 | $562,622 | $493,102 | $427,062 | $520,926 | $396,236 |
| Operating income | -$1.27M | -$1.36M | -$1.33M | -$1.45M | -$1.46M | -$952,189 | -$1.22M | -$729,594 |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Pretax income | -$1.25M | -$1.33M | -$1.31M | -$1.44M | -$1.44M | -$938,146 | -$1.19M | -$688,884 |
| Net income | -$1.25M | -$1.33M | -$1.31M | -$1.44M | -$1.44M | -$938,146 | -$1.19M | -$688,884 |
| EBITDA | -$1.27M | -$1.36M | -$1.33M | -$1.45M | -$1.46M | -$950,818 | -$1.22M | -$728,871 |
| EPS (basic) | -0.28 | -0.31 | -0.64 | — | -1.29 | -0.99 | -1.31 | — |
| EPS (diluted) | -0.28 | -0.31 | -0.64 | — | -1.29 | -0.99 | -1.31 | — |
| Weighted avg. shares (diluted) | 4.55M | 4.31M | 2.06M | — | 1.12M | 950,669 | 911,515 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.86M | $2.78M | $4.23M | $2.18M | $1.35M | $1.19M | $2.11M | $3.29M |
| Receivables | — | — | — | $84,713 | $31,079 | $35,332 | $68,934 | $32,286 |
| Current assets | $2.08M | $3.44M | $4.82M | $2.62M | $2.08M | $2.08M | $3.01M | $3.43M |
| PP&E, net | $7,699 | $8,420 | $9,142 | $9,864 | $10,585 | $11,307 | $12,029 | $12,750 |
| Total assets | $2.35M | $3.72M | $4.86M | $2.67M | $2.16M | $2.18M | $3.14M | $3.58M |
| Current liabilities | $642,399 | $746,898 | $776,846 | $754,417 | $701,186 | $480,313 | $551,881 | $385,355 |
| Total liabilities | $862,215 | $978,534 | $776,847 | $754,417 | $701,186 | $480,313 | $575,878 | $432,726 |
| Shareholders' equity | $1.49M | $2.74M | $4.08M | $1.92M | $1.46M | $1.70M | $2.56M | $3.14M |
| Shares outstanding | 4.62M | 4.47M | 2.55M | 1.21M | 1.09M | 7.61M | 7.04M | 756,743 |
| Cash flow statement | ||||||||
| Operating cash flow | -$926,057 | -$1.43M | -$1.43M | -$990,413 | -$653,103 | -$918,792 | -$1.39M | -$727,710 |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$727,710 |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $0 | -$10,047 | $3.47M | $1.82M | $820,332 | $0 | $200,000 | $1.61M |
| Depreciation & amortization | $722 | $721 | $722 | $721 | $722 | $1,371 | $721 | $723 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.